OCULAR THERAPEUTIX, INCOCUL

時価総額

$22.6億

PER

網膜治療のバイオ医薬品の新興企業。持続投与型点眼剤DEXTENZAを主力、AXPAXLIを開発。2024年2月の私募で32,413,560株を発行、同年の純損失は1.935億ドル、従業員数274名。米国中心に展開。

	2014年 12月31日	2015年 12月31日	2016年 12月31日	2017年 12月31日	2018年 12月31日	2019年 12月31日	2020年 12月31日	2021年 12月31日	2022年 12月31日	2023年 12月31日	2024年 12月31日
Net loss	-	-	-	-	-60	86	-156	-7	-71	-81	-194
Share-based Compensation	3	5	6	7	7	9	8	15	17	18	33
Non-cash interest expense	0	0	0	0	0	4	4	5	5	6	4
Change in fair value of derivative liabilities	-	-	-	-	-	-	-	-	-	-5	-0
Depreciation and amortization expense	1	1	1	2	2	3	3	2	2	3	4
Gains and losses on extinguishment of debt, net	-0	-	-	-	-	-	-	-	-	14	-28
Gain on disposal of property and equipment	-0	0	-1	0	-	-0	-	0	-0	-0	-
Accounts receivable	0	-0	0	-0	-0	2	10	9	0	5	6
Prepaid expenses and other current assets	0	0	-1	-0	0	1	2	0	-1	4	6
Inventory	0	0	-0	0	0	1	0	0	1	0	1
Accounts payable	1	0	-0	1	-1	0	-0	2	-1	1	-0
Operating lease assets	-	-	-	-	-	-1	-1	-1	3	-2	-1
Accrued expenses	2	0	1	3	2	2	2	4	2	1	4
Deferred revenue	-	-	-	-	-	-	12	1	1	0	-0
Operating lease liabilities	-	-	-	-	-	-1	-1	-1	3	-2	-1
Net cash used in operating activities	-	-	-	-50	-49	-78	-54	-66	-60	-70	-135
Purchases of property and equipment	1	2	2	8	2	2	1	1	4	6	1
Net cash used in investing activities	-	-	-	27	-2	-2	-1	-1	-4	-6	-1
Proceeds From Issuance of Protective Advance	-	-	-	-	-	-	-	-	-	2	-
Proceeds from Notes Payable	15	2	-	4	12	-	-	4	-	-	-
Proceeds from Stock Options Exercised	0	0	0	1	0	0	3	3	1	1	15
Proceeds from issuance of common stock pursuant to employee stock purchase plan	0	0	0	0	0	0	1	1	1	1	1
Payments of debt refinancing costs	-	-	-	-	-	-	-	-	-	5	-
Proceeds from Issuance of Common Stock	70	-	1	29	62	38	225	-	-	117	-
Repayment of MidCap notes payable	-	-	-	-	-	-	-	-	-	26	-
Repayment from issuance of short-term bridge loan	2	2	-	1	6	-	-	4	-	-	-
Proceeds from Issuance of Private Placement	-	-	-	-	-	-	-	-	-	-	316
Net cash provided by financing activities	-	-	-	32	69	75	228	3	1	170	332
Net increase in cash, cash equivalents and restricted cash	-	-	-	-	18	-4	174	-64	-62	94	196
Interest Paid	-	-	-	1	2	2	2	2	2	5	22
Capital Expenditures Incurred but Not yet Paid	0	0	0	1	0	0	0	0	1	0	0